DOCA sensitive pendrin expression in kidney, heart, lung and thyroid tissues.

[pendred syndrome]

Pendrin (SLC 26 A 4 ), a transporter accomplishing anion exchange , is expressed in inner ear , thyroid gland , kidneys , lung , liver and heart . Loss or reduction of function mutations of SLC 26 A 4 underlie Pendred syndrome , a disorder invariably leading to hearing loss with enlarged vestibular aqueducts and in some patients to hypothyroidism and goiter . Renal pendrin expression is up-regulated by mineralocorticoids such as aldosterone or deoxycorticosterone (DOCA ). Little is known about the impact of mineralocorticoids on pendrin expression in extrarenal tissues .The present study utilized RT-qPCR and Western blotting to quantify the transcript levels and protein abundance of Slc 26 a 4 in murine kidney , thyroid , heart and lung prior to and following subcutaneous administration of 100 mg /kg DOCA .Slc 26 a 4 transcript levels as compared to Gapdh transcript levels were significantly increased by DOCA treatment in kidney , heart , lung and thyroid . Accordingly pendrin protein expression was again significantly increased by DOCA treatment in kidney , heart , lung and thyroid .The observations reveal mineralocorticoid sensitivity of pendrin expression in kidney , heart , thyroid and lung .

Diseases
Validation

Diseases presenting "reduction of function mutations" symptom

pendred syndrome

You can validate or delete this automatically detected symptom